We further showed an AURKB inhibitor barasertib is more efficacious in neuroblastoma with MYCN amplification and wild-type TP53. Finally, we demonstrated barasertib significantly suppressed tumor growth in a human neuroblastoma xenograft mouse model. This evidence concerns the gene MYCN and neoplasm.